Tagrisso 40mg Tablets

About

Tagrisso (osimertinib) represents a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) specifically engineered to target both EGFR-sensitizing mutations (Ex19del, L858R) and the acquired EGFR T790M resistance mutation. Its mechanism of action involves the irreversible, covalent binding to specific cysteine residues within the ATP-binding pocket of the EGFR kinase domain. This binding effectively inhibits downstream signaling pathways, such as the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, which are critical for cell proliferation, survival, and angiogenesis in cancer cells. This highly targeted approach makes osimertinib particularly effective in treating non-small cell lung cancer (NSCLC) patients whose tumors harbor these specific EGFR mutations, both as a first-line therapy and following progression on earlier-generation EGFR TKIs. Its ability to cross the blood-brain barrier also provides a significant advantage in managing central nervous system metastases, a common challenge in advanced NSCLC.

Uses

• First-line treatment for metastatic EGFR mutation-positive NSCLC.
• Treatment of metastatic EGFR T790M mutation-positive NSCLC.
• Adjuvant therapy after tumor resection in EGFR mutation-positive NSCLC.
• Management of NSCLC with specific EGFR exon 19 deletions or exon 21 L858R mutations.

Directions For Use

Take one tablet orally once daily, with or without food, as prescribed by your oncologist. Do not crush, chew, or split the tablet.

Benefits

• Targets specific EGFR mutations, including T790M resistance.
• Demonstrates significant progression-free survival benefits.
• Effective in both first-line and second-line settings for NSCLC.
• Can penetrate the blood-brain barrier, addressing CNS metastases.
• Offers a targeted therapy approach with improved outcomes.
• Generally well-tolerated compared to traditional chemotherapy.

Side Effects

• Diarrhea
• Rash
• Dry skin
• Nail disorders (e.g., paronychia)
• Stomatitis
• Fatigue
• Decreased appetite
• Interstitial lung disease (ILD)
• QTc prolongation
• Cardiomyopathy
• Keratitis
• Thrombocytopenia

Safety Measures

• Alcohol - Avoid or limit alcohol consumption, as it may exacerbate certain side effects like liver issues or gastrointestinal upset.
• Pregnancy - Tagrisso can cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for 6 weeks after the last dose.
• Breastfeeding - It is unknown if osimertinib is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended.
• Liver - Use with caution in patients with hepatic impairment. Liver function tests should be monitored regularly during treatment.
• Kidney - No dose adjustment is recommended for mild to moderate renal impairment. Use with caution in severe renal impairment, as data are limited.
• Lung - Patients should be monitored for symptoms of interstitial lung disease (ILD), which can be severe or fatal. Discontinue if ILD is suspected.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.